Tecentriq® (atezolizumab) – New orphan indication
December 9, 2022 - The FDA announced the approval of Genentech’s Tecentriq (atezolizumab), as a single agent, for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS).
Top